H. Un. Virgen de la Arrixaca
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Perianes, Valentín Cabañas
GEM21menos65, NCT05558319: NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

Not yet recruiting
3
480
Europe
Bortezomib, Isatuximab, Iberdomide, Lenalidomide, Dexamethasone
PETHEMA Foundation, Bristol-Myers Squibb, Sanofi, Adknoma, Start from scratch
Newly Diagnosed Multiple Myeloma
04/27
04/29
GEM-BELA-VRd, NCT04802356: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Recruiting
2
50
Europe
Belantamab mafodotin, Blenrep, Bortezomib, Lenalidomide, Dexamethasone, Autologous stem cell transplant (ASCT)
PETHEMA Foundation, GlaxoSmithKline
Multiple Myeloma
03/25
07/25
CASSANDRA, NCT05908409: A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

Recruiting
1/2
37
Europe
IDP-121
IDP Discovery Pharma S.L.
Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified, Chronic Lymphocytic Leukemia (CLL), Triple Hit Lymphoma
12/24
12/25
Cabañas, Valentín
ZN-d5-003, NCT05199337 / 2021-003008-42: Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

Completed
1/2
18
Europe, US, RoW
ZN-d5, Study Drug
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc., K-Group Alpha, Inc
Amyloidosis, AL Amyloidosis
02/24
02/24
NCT05297240: Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

Recruiting
N/A
170
Europe
Belantamab mafodotin
PETHEMA Foundation, GlaxoSmithKline
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
12/22
12/22

Download Options